US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by RetinalGeniX Technologies, Inc.
RetinalGenix Reports on its Science and Mission in Light of New AI-Driven Retinal Mapping Study
January 14, 2026
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
October 16, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
SEER
RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
October 01, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
September 25, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening
June 27, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs
May 05, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies Welcomes Dr. Taimour Langaee as Advisor for DNA GPS Pharmacogenetics Initiatives
June 13, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies to Participate at the 37th Annual Roth Conference
March 06, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies Breakthrough in Real-Time 24/7 Remote Ocular Monitoring
February 20, 2025
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX™ Technologies Inc. Granted a Patent for System And Method For Visualization Of Ocular Anatomy
February 22, 2024
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX™ Technologies Inc. Contracts With MEDsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
December 26, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board
December 21, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies Inc. Appoints Dessy Boneva, MD, FACS to the Board of Directors
December 04, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
December 01, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies Inc. Appoints Stephen Tannenbaum to the Company's Business Advisory Board
November 28, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs
November 09, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam™ Image Visualization Device
November 08, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX IRB Approved to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration
October 30, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies Inc. Focuses on Prevention of Blindness and Early Detection of Multiple Systemic Diseases
September 18, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGenix Technologies Inc. Announces the Addition of Fred Chasalow, Ph.D., to the Medical Advisory Board of DNA-GPS
August 28, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies Inc. Granted Patent for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
July 28, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies, Inc. Nears Completion of Institutional Review Board for Research on DNA/GPS Program
June 26, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
Retinalgenix Technologies, Inc. Expands Team to Hasten the Launch of DNA/GPS
June 07, 2023
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
RetinalGeniX Technologies, Inc. to Present at the Emerging Growth Conference Wednesday, October 26, 2022
October 24, 2022
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
Vinay Mehindru, MD, MBA Appointed to RetinalGenix Technologies Inc. Board of Directors
July 26, 2022
From
RetinalGeniX Technologies, Inc.
Via
GlobeNewswire
Tickers
RTGN
